Outcomes in patients (pts) with relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL) treated with systemic therapy from real world experience (ORCHID) study.

被引：0

作者：

Damaj, Gandhi Laurent

Hampp, Christian

Bachy, Emmanuel

Prochazka, Katharina

Jo, Jae-Cheol

Kim, Tae Min

Oberic, Lucie

Townsend, William

Jalbert, Jessica J.

Ma, Qiufei

Kamat, Siddhesh

Wang, Joy

Ambati, Srikanth R.

Mohamed, Hesham

Chaudhry, Aafia

Thorley, Eileen

Rippin, Gerd

Harnett, James

Thieblemont, Catherine

机构：

[1] Univ Hosp Sch Med, Hematol Clin, Inst Hematol, Caen, France

[2] Regeneron Pharmaceut Inc, Tarrytown, NY USA

[3] Hosp Civils Lyon, Dept Hematol, Lyon, France

[4] Univ Claude Bernard Lyon 1, Lyon, France

[5] Med Univ Graz, Univ Clin Internal Med, Dept Clin Hematol, Graz, Austria

[6] Univ Ulsan, Coll Med, Dept Hematol & Oncol, Ulsan Univ Hosp, Ulsan, South Korea

[7] Seoul Natl Univ Hosp, Seoul, South Korea

[8] Inst Univ Canc, Dept Hematol, Toulouse, France

[9] Univ Coll London Hosp, Canc Res UK, London, England

[10] Univ Coll London Hosp, UCL Canc Trials Ctr, London, England

[11] IQVIA Inc, Durham, NC USA

[12] IQVIA, Frankfurt, Germany

[13] Univ Paris Cite, Paris, France

[14] Hop St Louis, AP HP, Hematooncol, Paris, France

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

e19067

引用

页数：1